Christian Borel

Christian Borel


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2006 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Jean BourhisJean Bourhis
Jean Bourhis
FRFernando Rivera
Fernando Rivera
RMRicard Mesia
Ricard Mesia
AAAhmad Awada
Ahmad Awada
LGLionel Geoffrois
Lionel Geoffrois
AHAndreas Harstrick
Andreas Harstrick
Purpose: This was an open, randomized, multicenter, phase I/II study to investigate the safety and tolerability of cetuximab in the first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN). Patients and Methods: Treatment comprised cetuximab (initial dose 400 mg/m2 with subsequent weekly doses of 250 mg/m2) in combination with 3-week cycles of either cisplatin (100 mg/m2) or carboplatin (area under the curve, 5), each in combination with a 5-day infusion of fluorouracil (FU) at escalating doses of 600, 800, and 1,000 mg/m2/d. The study was divided into two phases: A, the first two cycles (6 weeks) focusing on the safety and tolerability of combination therapy; and B, the remaining time for those benefiting from therapy until disease progression or intolerable toxicity. Results: Fifty-three patients were enrolled onto the study. The incidence of dose-limiting toxicities in phase A was acceptable. The most common grade 3/4 adverse events in both groups were leucopenia (38%), asthenia (25%), vomiting (14%), and thrombocytopenia (15%), which are consistent with the known safety profiles of cetuximab, cisplatin/carboplatin, and FU. The overall response rate among patients was 36%, with no clear trend toward an increased efficacy at the highest dose of FU, and no impact of the concomitant chemotherapy regimens on cetuximab pharmacokinetics. Conclusion: The combination of cetuximab, cisplatin/carboplatin, and FU was reasonably well tolerated and active in recurrent/metastatic SCCHN, and merits additional investigation. An FU dose of 1,000 mg/m2/d in combination with cisplatin or carboplatin can be recommended for additional studies.

21 September 2020 in Cancers
Verified
Journal Article
Open access
PDF file
CBChristian Borel
Christian Borel
AJAlain C. Jung
Alain C. Jung
MBMickaël BURGY
Mickaël BURGY
Head and neck squamous cell carcinoma (HNSCC) in the recurrent or metastatic (R/M) setting is a devastating disease with a poor prognosis. Until recently, the reference first line treatment was the EXTREME protocol, which yields a 10.1 months median survival, and almost no effective treatment are available in second line. Immune checkpoint inhibitors (ICIs) have changed the prognosis of several metastatic solid tumors. Given their inflammatory profile and high mutational burden, HNSCC is a good candidate for ICIs treatments. First, a strong pembrolizumab efficacy signal was shown in the Keynote-012 Phase Ib study. Then, the phase III Checkmate-141 study validated the efficacy of nivolumab in platinum-resistant patients. Finally, the first line conquest is acquired since the final results of the keynote-048 phase III study that demonstrated the superiority of pembrolizumab versus EXTREME in CPS ≥ 1 patients, and with the addition of platinum and 5FU in all patients. However, the first line treatment landscape is not frozen. Two studies (Checkmate-651 and Kestrel) are investigating the efficacy of the combination of antibodies raised against CTLA-4 and PD-(L)1. Results are impatiently awaited. Further progress needs the use of new immunotherapeutic agents such as monalizumab or ICOS agonist rather in combination with an anti-PD(L)1. New associations of ICIs and chemotherapeutic or targeted therapeutic agents are also actively investigated. Finally, ICIs has to be studied in the locally advanced setting where there is a chance of cure. Several trials are testing the potential synergistic combination of ICIs with radiotherapy and platinum or cetuximab, or ICIs used in a neoadjuvant setting.

1 January 2013 in Oral Oncology
Verified
Journal Article
Closed access
JJJérémie Jégu
Jérémie Jégu
FBFlorence Binder-Foucard
Florence Binder-Foucard
CBChristian Borel
Christian Borel
MVMichel Velten
Michel Velten

5 August 2005 in Head & Neck
Verified
Journal Article
Closed access
PDF file
CTChristophe Le Tourneau
Christophe Le Tourneau
MVMichel Velten
Michel Velten
GJGuy-Michel Jung
Guy-Michel Jung
GBGuy Bronner
Guy Bronner
HFHenri Flesch
Henri Flesch
CBChristian Borel
Christian Borel

1 June 2013 in Oral Oncology
Verified
Journal Article
Closed access
FPFrédéric Peyrade
Frédéric Peyrade
DCDidier Cupissol
Didier Cupissol
LGLionel Geoffrois
Lionel Geoffrois
FRFREDERIC ROLLAND
FREDERIC ROLLAND
CBChristian Borel
Christian Borel
JGJoël Guigay
Joël Guigay

1 January 2008 in Acta Oto-Laryngologica
Verified
Journal Article
Closed access
CTChristophe Le Tourneau
Christophe Le Tourneau
GJGuy-Michel Jung
Guy-Michel Jung
CBChristian Borel
Christian Borel
GBGuy Bronner
Guy Bronner
HFHenri Flesch
Henri Flesch
MVMichel Velten
Michel Velten
Given that radiation therapy (RT) is currently initiated as soon as possible after surgery, our results indicate that the main prognostic factors of survival are pT and pN stages in patients treated with surgery and postoperative RT for locally advanced head and neck squamous cell carcinoma (HNSCC). To determine the prognostic factors for survival in patients treated with surgery and postoperative RT for locally advanced HNSCC. A retrospective study was performed on 308 consecutive patients treated from 1990 to 1998 with surgery and postoperative RT. In addition to histological factors, time-related factors were considered. The median age of the whole cohort was 56 years (range 35-83). Median follow-up was 98 months. Median interval from surgery to the start of RT was 44 days (range 18-157), while median RT duration was 52 days (range 22-115). From univariate analysis of overall survival, statistically significant prognostic factors were pT stage (p<0.0001), pN stage (p=0.008), RT duration (p=0.01) and total treatment time (p=0.02). Perineural invasion, perivascular invasion, extranodal spread and positive resection margins did not appear to be related to survival. From multivariate analysis, the only statistically independent prognostic factors appeared to be pT and pN stages.